On Oct 22, 2023, Amgen published results from their CodeBreaK 300 study on Lumakras and Vectibix's efficacy in treating chemo-resistant mCRC with KRAS G12C mutation.

The Synapse database launches a drug transaction library to assist users in the BD and strategy departments of pharmaceutical companies in gaining insights into global drug transaction intelligence.

The NMDA receptor (N-methyl-D-aspartic acid receptor) is a subtype of the ionotropic glutamate receptor, with a complex molecular structure and unique pharmacological properties.

This article summarized the latest R&D progress of strontium ranelate, the Mechanism of Action for strontium ranelate, and the drug target R&D trends for strontium ranelate.

Shanghai Huaota Biopharmaceutical's HB0034 anti-IL-36R monoclonal antibody injection was granted orphan drug designation by the U.S. FDA for the treatment of generalized pustular psoriasis (GPP).

This article summarized the latest R&D progress of oxitriptan, the Mechanism of Action for oxitriptan, and the drug target R&D trends for oxitriptan.

Neurokinin-1 (NK1) receptor antagonists are used for prevention of acute and delayed nausea and vomiting.

This article summarized the latest R&D progress of pamiparib, the Mechanism of Action for pamiparib, and the drug target R&D trends for pamiparib.

The 2023 ESMO congress selected Shanghai Junshi Biosciences' phase III trial, EXTENTORCH, on anti-PD-1 monoclonal antibody toripalimab for the LBA.

This article summarized the latest R&D progress of peginterferon beta-1a, the Mechanism of Action for peginterferon beta-1a, and the drug target R&D trends for peginterferon beta-1a.

AMP-activated protein kinase (AMPK) is a crucial enzyme that plays a central role in regulating energy balance within the human body.

This article summarized the latest R&D progress of pimavanserin tartrate, the Mechanism of Action for pimavanserin tartrate, and the drug target R&D trends for pimavanserin tartrate.